Group sales increased by 3.2% to EUR 555.3 mill. and Group operating result by 51.7% to EUR 23.6 mill

Offenburg, March 23, 2016 – At this year’s balance sheet press conference the Board of Management of MEDICLIN Aktiengesellschaft (MediClin) presented again good financial figures. In the 2015 FY Group sales were achieved in the amount of EUR 555.3 mill. The sales plus was EUR 17.3 mill. or 3.2% against previous year. “We consider this as reassurance that regarding our measurements to enhance the locations we have done a lot of thing properly. A demand-oriented offer of good medical services has enabled sales growth”, said Volker Feldkamp, CEO of MediClin AG. The answer to the question what has been the most demanding challenge during his time with MediClin, Feldkamp said: “To start a process of change requires a lot of energy, since to chance accustomed habits and to accept new requirements faces strong opposition.” And he added: “We achieved this with MediClin. MediClin is well prepared to meet the changed conditions of competition.” 

Group operating result (Group-EBIT) increased from EUR 15.6 mill. to EUR 23.6 mill. and the result attributable to shareholders of MediClin AG from EUR 8.5 mill. to EUR 16.5 mill. To this Jens Breuer, CFO, said: “The improvement of the Group-EBIT is due to the sales increase by 3.2 % and the fact that expenses increased significantly non-proportional to sales just by 1.7%. Economies of scale and a stringent cost control added to this effect.”

The largest share of sales growth posted the post-acute segment with EUR 16.5 mill. The segment achieved sales of EUR 330.9 mill. (previous year: EUR 314.4 mill.) The nursing care business area accounted for EUR 14.1 mill. contributing EUR 1.0 mill. to sales growth. Sales of the acute segment amounted to EUR 206.7 mill., thus being EUR 0.6 mill. below previous years value. The segment results of the post-acute and acute segment increased by EUR 4.0 mill. respectively EUR 0.5 mill. against previous year. In the post-acute segment higher staff costs could be more than compensated by significantly higher sales and lower material costs compared to the previous year. In the acute segment lower material costs and staff costs led to an increase of result despite a slight decrease in sales.

In the FY 2015 about EUR 27.0 mill. (previous year: EUR 21,0 mill.) were invested in capital expenditure including EUR 2.7 mill. (previous year: EUR 4.4 mill.) subsidies. As of December 31, 2015 cash and cash equivalents amounted to EUR 29.5 mill. (31.12.2014: EUR 26.3 mill.); the equity ratio was 51.3% (31.12.2014: 48.8%).